EBI's primary target market is a group of disorders commonly known as the systemic inflammatory response syndrome ("SIRS"), including the clinical condition known as sepsis. Of the various inflammatory disorders, sepsis causes the greatest negative economic and medical consequences.
It is the leading cause of death in hospital intensive care units worldwide, costing the US healthcare system an estimated $18 billion per year, and causing 1,400 deaths per day in the developed countries of the world. In SIRS/sepsis the body's immune system overreacts to an infection or other stress leading to severe organ damage and death. SIRS acts by triggering a series of chemical reactions in the body in a sequential, cascade,like process. In many cases, uncontrolled cascades result in death. The goal of the Company's therapeutic development initiative is to modulate the sequence of reactions in the immune cascade with patented small molecule sub-fractions of human hormones that attenuate an uncontrolled immune response. Our drug candidates have additional clinical applications involving similar inflammatory pathologies involved in radiation sickness, renal failure, avian flu and anthrax infections.
EA-230 has completed Phase I single and multi-dose clinical trials including the Phase I expansion, LPS Proof of Concept, without material adverse reactions and the Company is currently preparing for Phase II clinical trials.
